J. Weng et al., Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations, DIABETOLOG, 44(2), 2001, pp. 249-258
Aims/hypothesis. The aim of this study was to examine the putative role of
mutations in the insulin promoter 1 (IPF1) gene in early-onset diabetes.
Methods. We carried out mutation screening of the IPF1 gene in 115 Scandina
vian families with at least two members with onset of diabetes younger than
40 years. The allele frequencies were also tested in 183 unrelated patient
s with late-onset Type II (noninsulin-dependent) diabetes mellitus and in 9
2 nondiabetic control subjects.
Results. Two novel IPF1 variants (G212R and P239Q) and one previously repor
ted (D76N) IPF1 variant were identified in the 115 families (3.5%). The D76
N variant was found in one MODY3 family (S315fsinsA of HNF1 alpha) and also
in two families with late-onset Type II diabetes. The P239Q variant was id
entified in two families with early-onset diabetes including one with MODY3
(R272C of HNF1 alpha) and in three families with late-onset Type II diabet
es. Despite the fact that the variants did not segregate completely with di
abetes, the non-diabetic carriers of the IPF1 variants had increased blood
glucose concentrations (p < 0.05) and reduced insulin:glucose ratios (p < 0
.05) during an oral glucose tolerance test compared with non-diabetic famil
y members without these variants. In addition, when the G212R and P239Q var
iants were expressed in cells without IPF1 i.e.. Nes2y cells, both variants
showed about a 50% reduction in their ability to activate insulin gene tra
nscription compared to wild-type IPF1, as measured by reporter gene assay.
Conclusion/interpretation. Although mutations in the IPF-1 gene are rare in
early- (3.5%) and late-onset (2.7%) Type II diabetes, they are functionall
y important and occur also in families with other MODY mutations.